Skip to main content

Invesco Dynamic Biotechnology & Genome ETF (PBE)

NYSEARCA: PBE · IEX Real-Time Price · USD
74.80 0.13 (0.17%)
Oct 20, 2021 4:00 PM EDT - Market closed
Assets$291.53M
NAV$74.75
Expense Ratio0.58%
PE Ratio49.60
Shares Out3.90M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateMar 23, 2020
1-Year Return
-
Volume6,587
Open74.87
Previous Close74.67
Day's Range74.74 - 75.27
52-Week Low55.75
52-Week High84.86
Beta1.05
Holdings31
Inception DateJun 23, 2005

About PBE

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Asset ClassEquity
SectorBiotech
RegionNorth America
IssuerInvesco
Stock ExchangeNYSEARCA
Ticker SymbolPBE
Index TrackedDynamic Biotechnology & Genome Intellidex Index

Top 10 Holdings

44.52% of assets
NameSymbolWeight
CatalentCTLT5.42%
Bio-TechneTECH5.21%
RepligenRGEN4.99%
Gilead SciencesGILD4.76%
AmgenAMGN4.73%
IncyteINCY4.45%
IlluminaILMN4.43%
BiogenBIIB3.94%
XencorXNCR3.33%
Dynavax TechnologiesDVAX3.25%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Mar 23, 2020$0.02898Mar 31, 2020
Sep 24, 2018$0.00207Sep 28, 2018
Jun 16, 2017$0.21532Jun 30, 2017
Mar 17, 2017$0.05552Mar 31, 2017
Dec 16, 2016$0.1208Dec 30, 2016
Sep 16, 2016$0.02834Sep 30, 2016
Full Dividend History

News

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

1 month ago - Zacks Investment Research

Biotech ETFs Benefit From Moderna Dual Booster Shot News

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that ...

Other symbols:MRNAIBBJ
1 month ago - ETF Trends

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...

Other symbols:IBBJBIB
1 month ago - ETF Trends

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...

Other symbols:BIBIBBJ
1 month ago - ETF Trends

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

2 months ago - Zacks Investment Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

2 months ago - Zacks Investment Research

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

3 months ago - Zacks Investment Research

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

3 months ago - Kiplinger

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...

Other symbols:BBHFBT
4 months ago - ETF Trends

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Other symbols:BBCGNOMSBIOXBI
4 months ago - Zacks Investment Research

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decli...

Other symbols:BIIBBBHFBTIBBPKW
4 months ago - Benzinga

Play 3 Emerging ETF Trends to Follow Cathie Wood

Many would like to follow Ark Investment Management founder Cathie Wood's vision due to her success. She says that digital wallets and genomics will be the next two biggest disruptive trends after Tesla...

Other symbols:ARKKARKWBATTDRIVIPAY
6 months ago - Zacks Investment Research

Biopharma Here to Stay: The Long-Term Case for the PBE ETF

The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...

9 months ago - ETF Trends

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

9 months ago - Zacks Investment Research

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other symbols:BBHFBTPJPPPH
10 months ago - Zacks Investment Research

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...

Other symbols:BBHFBT
10 months ago - Benzinga

2 Biotech Funds Poised for a Healthy Breakout

Biotech stocks are likely to remain in focus through year end amid news surrounding COVID-19 vaccines and treatments.

Other symbols:IBB
10 months ago - Investopedia

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

Sector ETF report for PBE

11 months ago - Zacks Investment Research

ETFs That Gained the Most in One of Best Post-Election Rallies

Wall Street booked remarkable gains a day after the election on hopes of a divided Congress.

11 months ago - Zacks Investment Research

Biotech ETFs to Shine on Coronavirus Antibodies Progress

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Other symbols:ARKGBBHIBBXBI
1 year ago - Zacks Investment Research

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Other symbols:ARKGGNOMIDNA
1 year ago - Zacks Investment Research

Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol

The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.

Other symbols:ARKGBBHIBBXBI
1 year ago - Zacks Investment Research

3 Health Care ETFs Where Components Are Enduring Downgrades

After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.

Other symbols:BTECPTH
1 year ago - Benzinga

Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

Sector ETF report for PBE

1 year ago - Zacks Investment Research

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

Other symbols:BTECCNCRGERMIBBXBI
1 year ago - Kiplinger